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Abstract
Background: A substantial fall in high-density lipoprotein cholesterol (HDL-C)
during puberty in boys, but not girls, has been reported in Western populations.
The fall in boys is believed to be due to hormonal changes – androgens have
been shown to be associated with lower HDL-C, whereas oestrogens are asso-
ciated with higher HDL-C. The fall in HDL-C during puberty was not observed,
however, in a study of Moslem boys in Israel, nor in a group of Japanese boys. A
diet high in phyto-oestrogens may account for the lack of a fall in HDL-C in these
populations.
Objective: To examine the effect of dietary supplementation with phyto-oestrogens
on the HDL-C concentration of adolescent boys from a Western population. We
hypothesised that dietary supplementation of 50 mg of the isoflavones daidzein
and genistein would produce a 12% higher HDL-C concentration than in controls
at the end of a 6-week intervention period.
Design: A randomised controlled trial.
Setting: Hellyer College in Burnie (Tasmania, Australia).
Subjects: Adolescent boys (aged 16–18 years) were recruited through a letter sent
to parents. A total of 132 eligible participants enrolled and five subjects withdrew
from the trial.
Results: No significant increase in HDL-C was observed in the treatment group
(–0.02 mmol l–1, standard error (SE)50.03, P5 0.53) or the placebo group
(0.05 mmol l–1, SE5 0.03, P5 0.11).
Conclusions: Factors other than isolated dietary isoflavones may be responsible







The presence of certain coronary heart disease (CHD) risk
factors in childhood, including high-density lipoprotein
cholesterol (HDL-C), have been related to the develop-
ment of fatty streaks and plaques in the coronary arteries
in early life1,2. Moreover, low HDL-C in adult life is known
to be strongly related to risk of CHD3. These two separate
findings suggest that it is important to obtain an under-
standing of the factors that raise HDL-C in children.
Evidence from Western populations shows that HDL-C
falls substantially during puberty in boys, but remains
unchanged in girls4. However, two studies show that
what has been regarded as the ‘typical’ fall of HDL-C with
puberty in boys is not universal. Greenland et al.5 found a
10–20% fall in HDL-C between the ages of 9–10 years and
16–18 years among Jewish boys in Israel, whereas among
Moslem boys there was a rise in HDL-C between these
ages. Our group has previously published data compar-
ing Japanese, Australian and American boys from the
same age groups and found similar outcomes6. Australian
and US boys experienced a 10–20% fall in HDL-C and a
concomitant fall in total cholesterol (TC), while the
Japanese boys showed little change in HDL-C or TC.
The fall in HDL-C in puberty in boys has been thought
to be due to the associated hormonal changes – androgens
having been shown to be associated with lower HDL-C7
while oestrogens are associated with higher HDL-C8.
Other factors shown to have the potential to substantially
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alter HDL-C in adults are physical activity9, alcohol10 and
certain drugs such as HMG Co-A reductase inhibitors11. In
children, physical activity has been demonstrated to
elevate HDL-C in some studies but not others and the
effect appears less than in adults12. Obesity in children is
also associated with lower HDL-C13.
In our previous study6, differences in physical activity
and obesity seem unlikely to explain the higher HDL-C
concentrations in postpubertal Japanese boys. We did not
have alcohol consumption but this was examined in
the Israeli study and did not appear to account for the
difference found there. Given that the atypical HDL-C
concentration has been observed in both a developed
country, Japan, and the less developed Israeli Moslem
population, it seems more likely that it is due to a lifestyle
factor rather than a medical intervention. A common
genetic determinant would appear unlikely.
Diet is a plausible candidate and, looking at the
Japanese/Australian comparison, there are a number of
striking contrasts. Of the foods that the Japanese children
consume, soybean and its products are most like foods
that Moslem children in Israel might also consume. The
Moslem population in Israel is known to consume large
quantities of lentils and chick-peas which, like soybeans,
are legumes14. These foods, which are not commonly
consumed by the majority of Australian children, might
be expected to have an effect on HDL-C through their
influence on hormonal status. Soybeans, lentils and
chick-peas contain isoflavones – phyto-oestrogens – that
could mimic the effect of endogenous oestrogens14.
The small number of trials in children and adolescents
suggest that soybean products affect HDL-C in this age
group. Jacques et al.15 found a 5% rise in HDL-C in a
4-week intervention involving soy protein in 6–12-year-old
hypercholesterolaemic boys. While most of the trials have
involved whole soy or soy protein, there have been
interventions using isoflavones. Knight et al.16 observed a
large increase in HDL-C in postmenopausal women with
isoflavone intervention, although an Australian trial17 of
isoflavones in adult men and postmenopausal women
failed to find an effect on HDL-C.
The aim of the present study was to compare the effect
of 6 weeks of isoflavones supplementation to a placebo on
HDL-C in adolescent boys. We conducted the trial in
northern Tasmania, an area which suffers high mortality
from cardiovascular disease18 and where HDL-C concen-
trations in adults are lower than the national average19.
Subjects and methods
The study was conducted at Hellyer College in Burnie,
Tasmania (latitude 418S) in 1999. All male students who
were aged between 16 and 18 years and enrolled at the
college were eligible to participate. The students were
invited to participate though an information letter sent to
their parent or guardian, and through information
distributed through the school’s daily newsletter.
The start and finish of the trial was staggered over a
2-week period. The trial commenced between the 5th and
16th of July 1999 and concluded between the 15th and 26th
of August 1999. Subjects were randomly assigned to receive
Novasoy (Archer Daniels Midland Company) or identical
placebo taken as tablets once a day for a period of 6 weeks.
The treatment tablet, Novasoy, contained 50mg of iso-
flavone derived from soy protein of which 30mg was in the
aglycone form. Soy in the aglycone form was chosen as we
thought this would be most similar to soy being consumed
by Japanese children. The treatment and placebo tablets
contained the same excipients: dicalcium phosphate dihy-
drate, sorbitol and magnesium stearate. The placebo con-
tained a mixture of maltodextrin and caramel colour in
place of the isoflavone ingredient. The treatment and pla-
cebo tablets were identical in size (11mm diameter), shape
(round) and colour (mottled light brown). The treatment
tablets had a bitter taste if chewed; this was not the case
with the placebos. Subjects were instructed to swallow the
tablets without chewing.
During the school week, tablets were administered
daily, at approximately the same time each morning by
K.L.H. A record of compliance and the time was noted in
a diary. On weekends students were asked to have an
adult witness consumption of the tablet and sign a diary
verifying compliance and the time the tablet was taken.
The study was approved by and performed in accor-
dance with the ethical standards of the Human Research
Ethics Committee of the University of Tasmania (project
number H0003116).
Our hypothesis was that the treatment group would
achieve a greater increase in mean HDL-C than the
control group.
The primary outcome measure was serum HDL-C
concentration. Secondary outcome measures were serum
TC, low-density lipoprotein cholesterol (LDL-C) and
triacylglycerol (TAG) concentrations.
Fasting venous blood was collected from subjects at
baseline and at 6 weeks. Subjects fasted from 22.00 hours
the previous night and all samples were collected
between 08.00 and 11.00 hours. Blood collected for lipid
analysis was kept cool on ice after collection and cen-
trifuged (3000 rpm for 5 min) within 3 h.
The study was powered20 to detect a 12% difference in
mean HDL-C (equivalent to 0.15 mmol l–1) between
treatment and placebo groups at post-intervention.
Height, weight, waist and hip circumferences, four
skinfold measurements (triceps, biceps, subscapular and
suprailiac) and blood pressure were also measured at
baseline and at 6 weeks. Body mass index (kg m22) was
calculated from weight and height; waist-to-hip ratio was
calculated from the waist and hip circumferences; and
percentage body fat was calculated from the four skinfold
measures21. During the first week of the trial, physical
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activity was assessed using a pedometer (Omron HJ-003)
by measuring the average number of steps taken per day.
Tanner pubertal stage was self-assessed by questionnaire
using drawings made from Tanner’s photographs illustrat-
ing the five stages of pubertal development22. LDL-C was
calculated using the Friedewald formula: LDL-C ¼ TC
HDL-C  ðTAG=5Þ. No dietary restrictions were imposed;
however, all subjects completed a food-frequency ques-
tionnaire and were asked about their consumption of a
range of foods known to contain isoflavones.
The randomisation was determined by the manu-
facturer using computer-generated random numbers.
Tablets were contained in individually numbered zip-
locked plastic bags. Subjects were allocated the next
numbered bag of tablets, in the order determined by the
manufacturer, at their baseline appointment.
The person conducting the field work (K.L.H.) was not
aware at any stage during the trial period of the subject
allocation to treatment/control. The laboratory techni-
cians who analysed the blood and urine samples were
also blinded throughout the trial. The data analysts
(K.L.H., J.L.F. and C.L.B.) were not given access to the
code until the trial was completed. Subjects and field
assistants were blinded. A copy of the code was sent to
the team by email and was not opened until the results of
the lipid analysis were available.
Subject compliance was assessed by tablet counts and
urinary assay of daidzein and genistein at baseline and
6 weeks by reverse-phase high-performance liquid chro-
matography as previously described23. The intra-assay and
inter-assay coefficients of variation were 3.74% and 10.23%
for daidzein, and 3.28% and 7.99% for genistein. Urine
samples were taken from the first void of the morning.
Statistical analysis was performed using Stata Statistical
Software, release 8.0 (StataCorp, 2003). The primary
analysis was based on the intent-to-treat (ITT) principle,
with the last observation carried forward for subjects with
missing data. All subjects randomised to receive study
treatment were included in the ITT population.
Analysis of variance methods were used to estimate the
mean change in lipid values and the difference in mean
change between treatment and placebo groups, both
without and with adjustment for baseline levels of the
lipid outcome. The outcomes examined were change in
HDL-C, change in TC, change in ratio of TC to HDL-C,
LDL-C, change in ratio of LDL-C to HDL-C and change in
TAG. Results of statistical tests were regarded as stati-
stically significant if the associated P-values were less
than 0.05. A per-protocol analysis was also performed
whereby the analysis was restricted to subjects with a
diary compliance of at least 80%. To examine compliance,
the outcomes examined were change in daidzein and
change in genistein concentrations. Because these two
isoflavone measures were not normally distributed, the
regression model was applied to ranks of the data rather
than their actual values.
Results
Of the 297 boys eligible to participate, 136 volunteered
during the recruitment period. Four were excluded
because they were outside the age limits. Five subjects
withdrew during the trial. A total of 127 boys completed
the trial: 69 in the treatment group and 58 in the placebo
group. Figure 1 provides details of the progress through
the phases of the trial.
Baseline characteristics of the two groups are shown in
Table 1. There were no material differences in baseline
factors between those assigned to the isoflavone and
those assigned to the placebo.
Results of the urinary assay of compliance are shown
in Table 2. Isoflavone supplementation resulted in sig-
nificant increases in both urinary daidzein and genistein
concentrations compared with the placebo group (both
P, 0.001).
In a test of subject knowledge of allocation conducted
at the end of the trial, 11.6% and 10.3% of subjects in the
treatment and placebo group, respectively, correctly
surmised which group they were assigned to. The
remainder indicated that they did not know which
group they were in (76.8% and 82.8%) or they guessed
incorrectly (11.6% and 6.8%). There was no significant
difference between the knowledge of each group
(x25 0.05, P5 0.82).
Results of the trial are reported in Table 3. There was no
evidence of an increase in HDL-C in the treatment group;
instead their mean concentration of HDL-C decreased
slightly by 0.02mmol l–1. A small increase of 0.05mmol l21
in mean HDL-C was observed in the placebo group. After
adjusting for baseline HDL-C concentrations the placebo
group had a slight increase in mean HDL-C concentration
relative to the treatment group.
TC concentrations decreased more in the treatment
group than the control group, but the difference between
the two groups was not statistically significant after
adjusting for baseline TC concentrations.
The changes in TC/HDL-C ratio, LDL-C concentration,
LDL-C/HDL-C ratio and TAG concentration did not reach
statistical significance. Analysing the ratio of TC to HDL-C
on the log scale made no difference to the results.
We found no evidence of confounding by measures
of body fatness (body mass index, percentage of body
fat, waist circumference), physical activity (measured by
pedometer) or age.
Per-protocol analysis of subjects with a diary com-
pliance of $80% did not differ appreciably from the ITT
analysis and is not shown.
Discussion
The studies in Japanese children6 and Israeli Moslem5
children were observational studies comparing populations
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of different ethnic backgrounds. These studies did not
reveal the relevant cause of the differences in HDL-C in
postpubescent boys. In the present study we tested
whether isoflavones might be an important cause of the
difference in HDL-C, but our results do not support
this hypothesis. Neither do our results show an effect of
isoflavones on other lipids.
In this randomised controlled trial of supplementation
with isoflavones to the diet of 16–18-year-old Australian
boys, to the level of usual Japanese intakes, a greater
reduction in mean concentration of TC was observed in the
treatment group than the control group. Our primary out-
come measure was HDL-C, however, and this increased in
the placebo group relative to the treatment group. None of
these changes were statistically significant.
There are few previous studies examining the effect of
isoflavones, or soy protein in general, on lipids in chil-
dren and adolescents. In two clinical trials examining the
effect of soy protein on lipids in children with familial
hypercholesterolaemia, significant increases in HDL-C
and significant decreases in very-low-density lipoprotein
cholesterol were reported15,24. Most published studies
have been conducted on adults, and these also have
predominantly involved subjects with raised non-HDL
lipids or menopausal and perimenopausal women. These
studies tend to focus on the hypocholesterolaemic effects
of soy on TC and other non-HDL lipids.
Recent reviews indicate that the relationship between
consumption of soy protein, isoflavones and lipoproteins
is not a clear one. Significant increases in HDL-C in
Fig. 1 Flow diagram of progress through the phases of the trial (ITT – intention-to-treat; PP – per-protocol).
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hypercholesterolaemic men and women consuming
soy protein have been reported in some studies25–27.
However, a meta-analysis of 38 trails of soy protein by
Anderson et al.28 found only a non-significant increase in
HDL-C, and Howes et al.29 found that HDL-C did not
change in postmenopausal women with mild to moderate
hypercholesterolaemia supplemented with isoflavones
from red clover. In a recent review of 22 randomised trials
using isolate soy protein with isoflavones, Sacks et al.30
failed to find any significant effects on HDL-C, although
decreased LDL-C concentrations were observed.
Among adults with elevated cholesterol concentrations
most trials report a lowering of TC and LDL-C following
consumption of soy protein31. In adults with normal cho-
lesterol concentrations, though, soy protein does not
appear to impact on cholesterol concentration31. A review
of studies examining the effect of isoflavones, in particular,
found that while minor reductions in LDL-C and non-HDL
cholesterol have been reported, studies in which no
reduction was found were also identified32. A meta-
analysis of the effects of isoflavones by Yeung and Yu33
reported no significant effects on lipid concentrations.
Reasons for the lack of consistency in the results of
trials may be related to the type of dietary intervention. A
wide variety of soy-based interventions are reported,
including whole soy protein, isolated soy protein, soy
protein with and without isoflavones, isolated isoflavones
and specially manufactured foods high in soy. The
inconsistency could also be due to random variation
associated with the small sample size of many studies.
A recent meta-analysis34 reports that soy protein with
isoflavones intact resulted in significant decreases in TC,
LDL-C and TAG and a significant increase in HDL-C in
adults. Tablets containing extracted soy isoflavones, on
the other hand, did not have a significant effect in redu-
cing TC, although their effect on HDL-C is not stated. It is
noted, however, that only trials of greater than 12 weeks’
duration showed improvements in HDL-C and that
Table 1 Characteristics of study participants at baseline
Measure Treatment group (n571)* Placebo group (n561)*
Age at start of trial (years) 16.63 (0.68) 16.56 (0.62)
Daidzein (ngmmol21 creatinine) 19.06 (IQR 0.00, 77.21)-
-
30.75 (IQR 0.00, 55.65)y
Genistein (ngmmol21 creatinine) 10.52 (IQR 0.00, 38.59)-
-
11.5 (IQR 0.00, 34.16)y
HDL-C (mmol l21) 1.19 (0.24) 1.19 (0.26)z
TC (mmol l21) 4.35 (0.72) 4.18 (0.71)
TC/HDL-C ratio 3.77 (0.87) 3.68 (0.92)
TAG (mmol l21) 0.93 (0.37) 0.96 (0.46)
LDL-C (mmol l21)- 2.98 (0.66) 2.82 (0.65)z
LDL-C/HDL-C ratio 2.61 (0.81) 2.50 (0.83)z
Height (cm) 177.78 (6.92) 177.44 (6.86)
Weight (kg) 72.78 (9.75) 72.62 (12.99)
BMI (kg m22) 23.00 (2.75) 23.07 (3.61)
WHR 0.78 (0.03) 0.78 (0.04)
%BF 14.57 (4.71) 15.10 (5.59)
SBP (mmHg) 121.31 (12.94) 120.82 (13.26)
DBP (mmHg) 61.24 (7.00) 60.72 (7.80)
Tanner pubertal stage 4.47 (0.60) 4.57 (0.48)
HDL-C – high-density lipoprotein cholesterol; TC – total cholesterol; TAG – triacylglycerols; LDL-C – low-density lipoprotein cholesterol; BMI – body mass
index; WHR – waist-to-hip ratio; %BF – percentage body fat; SBP – systolic blood pressure; DBP – diastolic blood pressure; IQR – interquartile range.
*Mean change and standard deviation for all variables except daidzein and genistein, where median and IQR are given.
-LDL-C calculated using the Friedewald formula: LDL-C=TC2HDL-C2(TAG/5).
-
-
28/70 (40%) had non-detectable concentrations. Excludes one subject from treatment group for whom urine measures were not available.
y19/60 (32%) had non-detectable concentrations. Excludes one subject from placebo group for whom urine measures were not available.
zExcludes one subject for whom HDL-C measures were not available.
Table 2 Assessment of compliance: change in urinary isoflavone concentrations in treatment and placebo groups




change (IQR) Mean difference (SE) Mean Difference (SE)





319.93 (159.68, 550.98) 0.00 (214.32, 72.21) 436.57 (76.03) 445.36 (73.57) ,0.001
Genistein (ngmmol21
creatinine)
155.34 (78.07, 298.03) 0.00 (213.98, 23.94) 236.42 (43.17) 248.59 (42.64) ,0.001
IQR – interquartile range; SE – standard error.
*Excludes one subject who did not have a pre-intervention urine sample.
-Excludes four subjects who did not have a post-intervention sample.
-
-
Adjusted for the initial value of the urinary isoflavone concentrations.
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studies with greater than 80 mg (our study had 50 mg)
showed greater effects on the lipid profile.
In this study we examined the effect of isolated iso-
flavones on HDL-C concentration. A review by Erdman31
suggests that isolated isoflavones may not have the same
effect on lipids as isoflavones consumed as part of soy
protein. Soy protein containing isoflavones has been
shown to lower cholesterol significantly more than
soy protein without isoflavones35–37. For soy to have its
maximal effect on cholesterol, both soy protein and
isoflavones may be needed.
The part of the soy responsible for affecting lipids,
however, has not been clearly identified31,32. There is
increasing evidence that the various components of soy
protein act in synergy to bring about their effects on
lipids31. In addition to isoflavones, soy protein also con-
tains trypsin inhibitors, phytic acid, saponins and fibre –
all of which have been reported to be associated with
lowering non-HDL cholesterol31,38. Saponins, for exam-
ple, are present in soy protein isolate at three times the
concentrations of isoflavones39 and have been shown,
among a number of bioactivities, to reduce choles-
terol38,40. Our reason for choosing isolated isoflavones
was based on the hypothesis that the lack of a ‘usual’ fall
in HDL-C during puberty observed in both Japanese
boys6 and Moslem boys from Israel5 may be due to a diet
containing phyto-oestrogens that impact on hormonal
changes at this time. In the Japanese diet the source of
phyto-oestrogens is soy protein and in the Moslem diet,
chick-peas and lentils. However, chick-peas and lentils,
like soy protein, contain saponins as well as isoflavones41.
It is possible that more than one of these constituents
acting together may influence lipid concentrations.
In addition to the effects of isolated isoflavones vs.
soy-protein-containing isoflavones, the timing of the
consumption of dietary phyto-oestrogens should also be
considered. The fall in HDL-C in boys from Western
populations occurs during puberty4. The participants in
this trial were aged between 16 and 18 years and, based
on Tanner stage, were close to physical maturity. The
concentration of HDL-C in these boys had already
decreased from normal childhood levels. It is possible
that isoflavones may influence hormone production and
subsequent HDL-C concentrations at the beginning of
puberty, but have less effect afterwards. A major dif-
ference between our study population and the Japanese
and Moslem boys (who do not show a decrease in HDL-C
following puberty) is the consumption of isoflavones
prior to puberty. By conducting the trial on older
adolescents we may have missed the ‘window’ for influ-
encing hormone concentrations. Postpubertal concentra-
tions of endogenous male hormones may have affected
the responsiveness to phyto-oestrogens. We would have
preferred to conduct the study on pubescent boys but
were concerned about possible powerful side-effects on
bone and feminisation.
Lipid concentrations are known to vary on a day-to-day
basis. In our study lipids were measured only once at
each time point (pre- and post-intervention) in order
to reduce the burden on subjects. Had it been feasible to
make multiple measurements on each subject both pre-
and post-intervention, it is likely that random error would
have been reduced and the effects we observed would
have been larger and measured more precisely.
Our study has not provided evidence that isolated
isoflavones increase HDL-C in adolescent boys, but it
raises a number of questions about the role of phyto-
oestrogens, soy protein and dietary factors that may be
important in influencing HDL-C. Future studies could
possibly test the effects of isoflavones over a longer
period or in a younger group of subjects than used here,
though the ethics of administering plant oestrogens to
prepubescent boys in an experimental setting would be
an issue to consider. Further research on the bioactive
compounds of soy protein and how the various compo-
nents interact may also provide a better understand-
ing of the factors that influence HDL-C in children and
adolescents.
Acknowledgements
The study was funded by a grant from the National Health
and Medical Research Council of Australia (9937770).
Table 3 Intention-to-treat analysis: within-person change for treatment and control groups, and differences between treatment and
control groups









Measure (post – pre) (post – pre) (unadjusted values) (adjusted values*) P-value
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SE – standard error; HDL-C – high-density lipoprotein cholesterol; TC – total cholesterol; LDL-C – low-density lipoprotein cholesterol; TAG – triacylglycerols.
*Adjusted for the initial value of the lipid measure or ratio.
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